Subject
Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine
Reference49 articles.
1. “WHO Coronavirus (COVID-19) Dashboard”.Covid19.Who.Int, 2021, https://covid19.who.int/. Accessed 24 Dec 2021.
2. COVID-19: breaking down a global health crisis;Mallah;Ann Clin Microbiol Antimicrob,2021
3. Lives and Costs Saved by Expanding and Expediting COVID-19 Vaccination;Bartsch;J Infect Dis,2021
4. Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis 2021; 21(1): 39–51. doi:10.1016/ S1473-3099(20)30831-8.
5. https://cdn.who.int/media/docs/defaultsource/immunization/sage/2021/april/2_sage29apr2021_critical-evidence_sinopharm.pdf.
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Immunogenicity and real-world effectiveness of COVID-19 vaccines in Lebanon: Insights from primary and booster schemes, variants, infections, and hospitalization;PLOS ONE;2024-09-13
2. Designing an integrated sustainable-resilient mix-and-match vaccine supply chain network;Annals of Operations Research;2024-08-14
3. Heterologous booster vaccination enhances antibody responses to SARS-CoV-2 by improving Tfh function and increasing B-cell clonotype SHM frequency;Frontiers in Immunology;2024-06-21
4. Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up;International Immunopharmacology;2024-06
5. Safety and immunogenicity of heterologous boosting with a bivalent SARS-CoV-2 mRNA vaccine (XBB.1.5/BQ.1) in Chinese participants aged 18 years or more: A randomised, double-blinded, active-controlled phase 1 trial;Vaccine;2024-04